PETER ROST: PHARMA MARKETING EXPERT WITNESS. AWP, MEDICAL DEVICE EXPERT.: Pfizer board member dumped most of his PFE stock--his portfolio manager was unauthorized to trade, Pfizer says.
screen2largeMM

Dr. Rost provides services as a pharmaceutical marketing expert witness. For more info see: Drug Expert Witness. Dr. Peter Rost email. Copyright © 2006-2013 InSync Communication. All rights reserved. Terms of use agreement, privacy policy and the computer fraud and abuse act.
.

PETER ROST: PHARMA MARKETING EXPERT WITNESS. AWP, MEDICAL DEVICE EXPERT.

Peter Rost, M.D., is a former Pfizer Marketing Vice President providing services as a medical device and drug expert witness and pharmaceutical marketing expert. Judge Sanders: "The court agrees with defendants' view that Dr. Rost is a very adept and seasoned expert witness." He is also the author of Emergency Surgery, The Whistleblower and Killer Drug. You can reach him on rostpeter (insert symbol) hotmail.com. Please read the terms of use agreement and privacy policy for this blog carefully.

Pfizer board member dumped most of his PFE stock--his portfolio manager was unauthorized to trade, Pfizer says.

(Bloomberg) -- Pfizer Inc. board member James Kilts sold 86 percent of his Pfizer shares about the same time the company began talks to buy Wyeth, according to a regulatory filing that says the transaction occurred without his knowledge.

Kilts, 61, the former chief executive officer of Gillette Co., sold 13,905 Pfizer shares for $259,772 from June 3 to June 6, according to a U.S. Securities and Exchange Commission filing today. Kilts sold the shares for $18.99 to $18.30 each, at least 21 percent higher than today’s closing price of $14.38 in New York Stock Exchange composite trading.

Kilts’ portfolio manager sold the shares against Kilts’ instruction and without his knowledge, the filing said. Pfizer agreed Jan. 26 to buy Wyeth and cut its dividend in half. Both Pfizer and Wyeth said their negotiations began last summer, though they wouldn’t specify a date.

“Contrary to the direction of Jim Kilts’ explicit instructions not to engage in any transaction in Pfizer stock without his prior approval, Jim Kilts’ portfolio manager sold shares of Pfizer in early June 2008,” Pfizer spokesman Ray Kerins said in a statement. “Neither Mr. Kilts nor Pfizer was aware of these sales. Once Mr. Kilts became aware of these sales, he immediately notified Pfizer, and Pfizer made a prompt and appropriate disclosure on his behalf.”

Kilts still owns 2,200 Pfizer shares, the filing said.

The SEC requires company insiders to document share sales within two days. Kilts will be listed in Pfizer’s annual proxy statement as a late filer.

Kilts, the founding partner of private equity firm Centerview Partners LLP in New York, didn’t return a phone call left with his assistant.

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home